Earlier this year US pharmacy distribution group Omnicare Inc sold its contract research arm to private equity investor Nautic Partners.
CEO James Pusey told Outsourcing-pharma.com about developments since the acquisition at DIA 2011, explaining that one of the benefits of independence is accelerated decision making, especially in relation to technology.
“Historically we were only investing about three of four hundred thousand dollars a year in new technologies, which was not enough…now we have surpassed $3m per year.”
Dr Pusey added that the Theorem is also able to react more quickly to opportunities, citing intervention medical device trials as a growing area of demand for the firm.
He also predicted that the wave of private equity investments in contract research organisation (CRO) will continue as the pharmaceutical industry continues to evolve.
“The thing about private equity is that it tends to invest for the long term. It tends to think ‘how can we benefit from a financial return in a changing market? And how can we rapidly support a game changing situation?”